0 infection! Hundreds of thousands of domestically-made inactivated vaccines have been vaccinated

In an interview with the media on the emergency use of the new crown inactivated vaccine and overseas phase III clinical research, the head of Sinopharm China Biotechnology revealed that the two new crown inactivated vaccines developed by Sinopharm China Bio have been vaccinated for hundreds of thousands of times, and none of them is obviously bad. In response, no one was infected; among them, tens of thousands of people who went to overseas high-risk countries and regions after the vaccine had no infection so far.

　　 Zhou Song, the general counsel of Sinopharm China Biotechnology, said that three domestic new crown inactivated vaccines have been approved for clinical trials, and Sinopharm China Biotechnology accounts for two of them. It is currently the largest emergency vaccination and the largest number of people. Zhou Song emphasized that the more important thing is that the emergency use of the new crown inactivated vaccine is aimed at people with high risk exposures, such as medical staff who treat people infected with the new crown virus, as well as diplomats and foreigners going to high-risk countries. Dispatch employees and Chinese-funded enterprises "Belt and Road" construction personnel and so on. These tens of thousands of people have been overseas for a few months after being vaccinated. Among them, in the areas where the epidemic broke out, some left-behind employees were infected but they did not. Parallel control data like this is available in multiple countries, which proves the effectiveness of the vaccine.

　　, Zhang Yuntao, vice president of Sinopharm China Biology, said that phase I and II clinical studies of the new crown inactivated vaccine were carried out in China, and neutralizing antibodies were produced. "Neutralizing antibody testing is the gold standard." In overseas Phase III clinical studies, neutralizing antibodies will also be continuously observed. Neutralizing antibodies are comparable. Overseas trials have expanded races, countries, and populations, and most importantly, they have been recognized overseas, which will be better for future applications.

　　 Zhang Yuntao said that in the past, it was difficult for our vaccines to be exported. There were a series of regulations and clinical restrictions. Now that our scientific and technological strength is strong, the data of phase I and II clinical trials are recognized overseas, and the direct development of phase III clinical research overseas is a model of international cooperation. In the future, if China's approval is passed, as long as these countries do clinical research, they can also be legally listed on the market. He revealed that at present, there are 500 million doses of intentional orders for the new crown inactivated vaccine in the world.